Sign Out
Hypersensitivity to somatropin or to any of the excipients.
Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and anti-tumour therapy must be completed prior to starting GH therapy. Treatment should be discontinued if there is evidence of tumour growth.
Somatropin should not be used for growth promotion in children with closed epiphyses.
Somatropin should not be used in children with PWS and a corresponding severe respiratory disorder or severe obesity.
Patients with acute critical illness suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions should not be treated with somatropin.
The 5 mg/1.5 mL presentation contains benzyl alcohol, its use should be avoided in children under two years of age. Not to be used in Neonates.
Continue with Google